Literature DB >> 16947088

In utero haematopoietic stem cell transplantation. Experiences in mice, sheep and humans.

Carolyn Troeger1, Daniel Surbek, Andreina Schöberlein, Stephan Schatt, Lisbeth Dudler, Sinuhe Hahn, Wolfgang Holzgreve.   

Abstract

Early prenatal diagnosis and in utero therapy of certain fetal diseases have the potential to reduce fetal morbidity and mortality. The intrauterine transplantation of stem cells provides in some instances a therapeutic option before definitive organ failure occurs. Clinical experiences show that certain diseases, such as immune deficiencies or inborn errors of metabolism, can be successfully treated using stem cells derived from bone marrow. However, a remaining problem is the low level of engraftment that can be achieved. Efforts are made in animal models to optimise the graft and study the recipient's microenvironment to increase long-term engraftment levels. Our experiments in mice show similar early homing of allogeneic and xenogeneic stem cells and reasonable early engraftment of allogeneic murine fetal liver cells (17.1% donor cells in peripheral blood 4 weeks after transplantation), whereas xenogeneic HSC are rapidly diminished due to missing self-renewal and low differentiation capacities in the host's microenvironment. Allogeneic murine fetal liver cells have very good longterm engraftment (49.9% donor cells in peripheral blood 16 weeks after transplantation). Compared to the rodents, the sheep model has the advantage of body size and gestation comparable to the human fetus. Here, ultrasound-guided injection techniques significantly decreased fetal loss rates. In contrast to the murine in utero model, the repopulation capacities of allogeneic ovine fetal liver cells are lower (0.112% donor cells in peripheral blood 3 weeks after transplantation). The effect of MHC on engraftment levels seems to be marginal, since no differences could be observed between autologous and allogeneic transplantation (0.117% donor cells vs 0.112% donor cells in peripheral blood 1 to 2 weeks after transplantation). Further research is needed to study optimal timing and graft composition as well as immunological aspects of in utero transplantation.

Entities:  

Mesh:

Year:  2006        PMID: 16947088     DOI: 2006/31/smw-11380

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  11 in total

1.  Gene therapy: the promise of a permanent cure.

Authors:  Christopher D Porada; Christopher Stem; Graca Almeida-Porada
Journal:  N C Med J       Date:  2013 Nov-Dec

2.  Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.

Authors:  Christopher Stem; Christopher Rodman; Ritu M Ramamurthy; Sunil George; Diane Meares; Andrew Farland; Anthony Atala; Christopher B Doering; H Trent Spencer; Christopher D Porada; Graça Almeida-Porada
Journal:  Front Cell Dev Biol       Date:  2021-08-10

3.  Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance.

Authors:  Takenao Chino; Katsuto Tamai; Takehiko Yamazaki; Satoru Otsuru; Yasushi Kikuchi; Keisuke Nimura; Masayuki Endo; Miki Nagai; Jouni Uitto; Yasuo Kitajima; Yasufumi Kaneda
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

4.  Phenotypic changes of human cells in human-rat liver during partial hepatectomy-induced regeneration.

Authors:  Yan Sun; Dong Xiao; Hong-An Li; Jin-Fang Jiang; Qing Li; Ruo-Shuang Zhang; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

5.  Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery.

Authors:  Christopher D Porada; Graça Almeida-Porada
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-25

6.  Development and characterization of a novel CD34 monoclonal antibody that identifies sheep hematopoietic stem/progenitor cells.

Authors:  Christopher D Porada; Duygu D Harrison-Findik; Chad Sanada; Vincent Valiente; David Thain; Paul J Simmons; Graça Almeida-Porada; Esmail D Zanjani
Journal:  Exp Hematol       Date:  2008-12       Impact factor: 3.084

7.  Transplantation tolerance induced in humans at the fetal or the neonatal stage.

Authors:  Jean-Louis Touraine; Kamel Sanhadji
Journal:  J Transplant       Date:  2011-08-18

Review 8.  Hemophilia A: an ideal disease to correct in utero.

Authors:  Christopher D Porada; Christopher Rodman; Glicerio Ignacio; Anthony Atala; Graça Almeida-Porada
Journal:  Front Pharmacol       Date:  2014-12-11       Impact factor: 5.810

Review 9.  Prenatal stem cell therapy for inherited diseases: Past, present, and future treatment strategies.

Authors:  Åsa Ekblad-Nordberg; Lilian Walther-Jallow; Magnus Westgren; Cecilia Götherström
Journal:  Stem Cells Transl Med       Date:  2019-10-24       Impact factor: 6.940

Review 10.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.